Corhepta Pharmaceuticals, Inc.

Inhibikase Therapeutics, Inc. (NasdaqCM:IKT) acquired CorHepta Pharmaceuticals, Inc. for $14.8 million on February 21, 2025. The consideration consists of 4,979,101 shares of the Company?s common stock, to the former stockholders of CorHepta, of which 3,319,397 were issued as upfront consideration. 82,979 Consideration Shares of the Upfront Consideration were deposited in a twelve-month escrow for purposes of satisfying potential indemnity obligations of the CorHepta Stockholders under the Merger Agreement. The remaining Consideration Shares were issued as contingent consideration, which will vest upon achievement of a certain milestone. If the vesting condition is not satisfied as of the first anniversary of the Closing Date, then the Contingent Consideration will be forfeited.

Inhibikase Therapeutics, Inc. (NasdaqCM:IKT) completed the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025.